Program
trastuzumab deruxtecan
Also written as “Trastuzumab deruxtecan”, “Trastuzumab Deruxtecan” and “DS-8201a”.
Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Neoplasm Metastasis · Endometrial Neoplasms, led by 4 companies.
Drug pageTrastuzumab deruxtecan: every studyAll 120 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daiichi Sankyoits history only | 2611 open or running | phase 3since Apr 13, 2018 | Sep 21, 2015 | Oct 1, 2027phase 3 · NCT05950945 |
| AstraZenecaits history only | 2120 open or running | phase 4since May 21, 2024 | Sep 22, 2017 | Feb 10, 2027phase 2 · NCT06271837 |
| Pfizer | 10 open or running | phase 2since Aug 31, 2020 | Aug 31, 2020 | none ahead |
| Strata Oncologyits history only | 10 open or running | phase 2since Oct 1, 2021 | Oct 1, 2021 | none ahead |
Also a collaborator on its studies: Parexel, Merck, Bristol-Myers Squibb and Gilead Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pfizer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2016Named trastuzumab deruxtecanINNProposed as its International Nonproprietary Name in WHO's List 116
- Aug 31, 2020First study: phase 2 study in Breast NeoplasmsFirst studyNCT04539938 · 70 enrolled · United States
TargetBeta
“An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) ”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 binding agent”ChEMBL 37, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
The one study Pfizer leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04539938Breast Neoplasms · United States | 2 | Completed | Jul 15, 2024 | 70 |
How it is read
Names in the registry
- “Trastuzumab deruxtecan”, 22 entries
- “Trastuzumab Deruxtecan”, 10 entries
- “DS-8201a”, 7 entries
- “Trastuzumab deruxtecan (DS-8201a)”, 3 entries
- “T-DXd”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 19 studies
- Carcinoma, Non-Small-Cell Lung, 7 studies
- Stomach Neoplasms, 5 studies
- Neoplasm Metastasis, 4 studies
- Endometrial Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.